The APAC fluorescent immunoassay market is expected to grow from US$ 503.91 million in 2021 to US$ 811.10 million by 2028; it is estimated to grow at a CAGR of 7.0% from 2021 to 2028.
Fluorescent dyes or fluorophores have been widely used as probes (for physical and structural parameters), indicators (e.g., for molecular concentrations), or labels/tracers (e.g., for visualization and localization of biomolecules) in various bioassays. Therefore, the development of fluorescent dyes, accompanied by appropriate devices and their applications, has significantly impacted the healthcare sector. New technologies, materials, and devices have been developed to detect and utilize fluorescence signals in biological samples efficiently. The need for sensitive and inexpensive diagnostic tools has led to new strategies to enhance the fluorescence signal of diagnostic assays, including improving the surface immobilization of biomolecules, increasing the density of fluorescent labels per binding event, and improving the optical properties of fluorescent reporters. One way to enhance fluorescence performance is to develop fluorescent dyes with improved brightness, photostability, quantum yield, and Stokes shift. Fluorescent labels have also been used to create homogeneous immunoassays by various techniques. Fluorescein isothiocyanate (FITC) is an organic fluorescent dye and probably one of the most used in immunofluorescence and flow cytometry. It can be coupled to various antibodies using its reactive isothiocyanate group, which binds to amino, sulfhydryl, imidazolyl, tyrosyl, or carbonyl groups of proteins. FITC was one of the first dyes used for fluorescence microscopy and served as a precursor to other fluorescent dyes. Its fluorescence activity is due to its extensive conjugated aromatic electron system, which is excited by the blue light spectrum. Therefore, due to the increase in the development of fluorescent dyes and instruments, the fluorescent immunoassays market is expected to grow in the coming years.
With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC fluorescent immunoassay market at a notable CAGR during the forecast period.
APAC Fluorescent Immunoassay Market Revenue and Forecast to 2028 (US$ Million)
APAC Fluorescent Immunoassay Market Segmentation
The APAC fluorescent immunoassay market is segmented into product type, application, end user, and country. Based on product type, the market is segmented into ELISA, rapid lateral flow immunoassay, and others. The ELISA segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on application, the market is segmented into infectious diseases, oncology, cardiovascular diseases, and others. The infectious disease segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on end user, the market is segmented into hospitals & clinics, diagnostic centers, pharmaceutical & biotechnology companies, academic & research institutes, and others. The hospitals and clinics segment dominated the market in 2021 and is expected to be fastest growing during forecast period. Based on country, the APAC fluorescent immunoassay market is segmented into China, Japan, India, South Korea, Australia, and the Rest of APAC.
Abbott, BD, bioMerieux SA, Danaher, F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, Siemens AG, Sysmex Corporation, and Thermo Fisher Scientific Inc. are among the leading companies operating in the APAC fluorescent immunoassay market.